gilteritinib + atezolizumab

**Gilteritinib + atezolizumab** is a combination of two distinct anticancer agents: gilteritinib, a small molecule inhibitor of FLT3 (FMS-like tyrosine kinase 3) and AXL receptor tyrosine kinases, and atezolizumab, a humanized monoclonal antibody checkpoint inhibitor targeting PD-L1 (Programmed death-ligand 1). Gilteritinib is approved for relapsed/refractory acute myeloid leukemia (AML) with FLT3 mutations, functioning by selectively inhibiting mutant and wild-type FLT3 as well as AXL, thereby blocking key signaling pathways (STAT5, ERK, AKT) involved in leukemic cell proliferation[1][2][3][6][9]. Atezolizumab blocks the interaction between PD-L1 and PD-1, leading to restoration of anti-tumor immune responses[8]. \nThe combination is under investigation for enhanced leukemia clearance and immune activation in relapsed/refractory AML[5][7].

Brand names

atezolizumab (Tecentriq)

Other names

gilteritinibatezolizumab